The Multiple Myeloma Research Foundation (MMRF) helps accelerate the development of next generation multiple myeloma treatments to extend patient’s lives, and lead to a cure. MMRF brings treatment to multiple myeloma patients 60% faster than the average through collaboration with best in class partners in the US and Internationally. In the process, we are changing the way cancer research is conducted. MMRF, a 501(c)(3), is the number one private funder of multiple myeloma research in the United States.
Discoveries, trials, research and more. Sign up for the MMRF newsletter.
The MMRF mourns the loss of our dear friend, inspiration and hero – Elie Wiesel. Read More
Join us at the 2016 MMRF San Francisco Patient Summit on 8/6 for a day of myeloma insights and education Register Now
MMRF Founder Kathy Giusti to Co-Chair Harvard Business School/Kraft Precision Medicine Accelerator Read More
Leaders Applaud MMRF Precision Medicine Model at the Milken Institute Global Conference Watch Now
Kathy Giusti sits down with Dr. Nancy Snyderman at the 2016 World Medical Innovation Forum
"These 3 Former Business Leaders Are Disrupting Medicine" Read more
"Kathy Giusti: The Cancer Patient Who Became an Advocate for Precision Medicine" Read more
Learn more about Kathy Giusti and the MMRF at the 2016 Precision Medicine World Conference Learn more
Read how MMRF Founder Kathy Giusti took a business approach to cancer advocacy Read More
The MMRF and "New Weapons in the Fight Against Multiple Myeloma". Read More
Connect with patients, engage with experts, get the information you need! MMRF CoMMunity Gateway
At the MMRF, we’re urgently working to develop treatments to extend your life. We can notify you about clinical trials, connect you to other patients with the same disease characteristics, bring you the latest breaking developments, and more. We’re learning every day. You can too.LEARN MORE
The model we have created for drug discovery and development is revolutionary. It brings multiple myeloma treatments to trial 60% faster than average. It has resulted in 10 multiple myeloma drugs receiving FDA approval in the time it normally takes for one. Through the power of new technology, genomics and immunology, it has extended lives that would have been lost to multiple myeloma yesterday. And it is accelerating all the time. Learn how we are doing it.